Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

Annals of Neurology

Volumn 76, Issue 6, 2014, Pages 802-812

  Plavina, Tatiana ^a   Subramanyam, Meena ^a   Bloomgren, Gary ^a   Richman, Sra ^a   Pace, Amy ^a   Lee, Sophia ^a   Schlain, Brian ^a   Campagnolo, Denise ^a   Belachew, Shibeshih ^a   Ticho, Barry ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ALGORITHM; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL STUDY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; JC VIRUS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PATIENT RISK; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LONGITUDINAL STUDY; METABOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; BIOMARKERS; HUMANS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; LONGITUDINAL STUDIES; NATALIZUMAB; RISK FACTORS;

EID: 84913555304     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24286     Document Type: Article

References (36)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
2. O'Connor P, Goodman A, Kappos L, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology 2014;83:78-86.
3. Butzkueven H, Kappos L, Pellegrini F, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014 Feb 14 [Epub ahead of print].
4. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-1880.
5. Biogen Idec. Medical information website. Available at: https://medinfo.biogenidec.com/medinfo. Accessed September 2012 to August 30, 2014.
6. Bozic C, Richman S, Plavina T, et al. Anti-JCV antibody prevalence in patients with relapsing multiple sclerosis receiving or considering treatment with natalizumab: baseline results of STRATIFY-2. Neurology 2012;78[Meeting Abstracts 1]:S41.002.
7. Bozic C, Richman S, Plavina T, et al. Anti-John Cunningham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol 2011;70:742-750.
8. Olsson T, Achiron A, Alfredsson L, et al. Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Mult Scler 2013;19:1533-1538.
9. Outteryck O, Ongagna JC, Duhamel A, et al. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy. J Neurol 2012;259:2293-2298.
10. Trampe AK, Hemmelmann C, Stroet A, et al. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012;78:1736-1742.
11. Plavina T, Lee S, Berman M, et al. Longitudinal stability of anti-JC virus antibody status in multiple sclerosis patients: results of STRATIFY-1. Neurology 2013;80:S30.001.
12. Lee P, Plavina T, Castro A, et al. A second generation ELISA (STRATIFY JCVTM DxSelectTM) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013;57:141-146.
13. Bohl DL, Brennana DC, Ryschkewitschc C, et al. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 2008;43:184-189.
14. Pastrana DV, Wieland U, Silling S, et al. Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer. Med Microbiol Immunol 2012;201:17-23.
15. Touźe A, Le Bidre E, Laude H, et al. High levels of antibodies against Merkel cell polyomavirus identify a subset of patients with Merkel cell carcinoma with better clinical outcome. J Clin Oncol 2011;29:1612-1619.
16. Plavina T, Subramanyam M, Bloomgren G, et al. JCV antibody index stratifies PML risk in natalizumab-treated MS patients. Available at: https://cmscactrims.confex.com/cmscactrims/ 2013/webprogram/Paper1642.html. Accessed November 25, 2013.
17. rd Annual Meeting of the European Neurological Society; June 8-11, 2013; Barcelona, Spain.
18. TM prescribing information, 2013. Available at: http://www.focusdx.com/pdfs/pi/US/ EL1950.pdf. Accessed November 25, 2013.
19. Randhawa PS, Gupta G, Vats A, et al. Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol 2006;13:1057-1063.
20. Besson C, Amiel C, Le-Pendeven C, et al. Positive correlation between Epstein-Barr virus viral load and anti-viral capsid immunoglobulin G titers determined for Hodgkin's lymphoma patients and their relatives. J Clin Microbiol 2006; 44:47-50.
21. Drouet E, Brousset P, Fares F, et al. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J Med Virol 1999;57:383-389.
22. Stevens SJ, Blank BS, Smits PH, et al. High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: correlation with antiretroviral therapy and quantitative EBV serology. AIDS 2002;16:993-1001.
23. Gosert R, Rinaldo CH, Funk GA, et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008;205:841-852.
24. Randhawa P, Zygmunt D, Shapiro R, et al. Viral regulatory region sequence variations in kidney tissue obtained from patients with BK virus nephropathy. Kidney Int 2003;64:743-747.
25. Olsen GH, Andresen PA, Hilmarsen HT, et al. Genetic variability in BK virus regulatory regions in urine and kidney biopsies from renal transplant patients. J Med Virol 2006;78:384-393.
26. Nakamichi K, Kishida S, Tanaka K, et al. Sequential changes in the non-coding control region sequences of JC polyomaviruses from the cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. Arch Virol 2013;158: 639-650.
27. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003;54:535-551.
28. Masutani K, Ninomiya T, Randhawa P. HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia. Nephrol Dial Transplant 2013;28:3119-3126.
29. Outteryck O, Zéphir H, Salleron J, et al. JC-virus seroconversion in multiple sclerosis patients receiving natalizumab. Mult Scler 2014; 20:822-829.
30. th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); October 2-5, 2013; Copenhagen, Denmark.
31. Berger JR, Houff SA, Gurwell J, et al. JC virus antibody status underestimates infection rates. Ann Neurol 2013;74: 84-90.
32. Major EO, Frohman E, Douek D. JC viremia in natalizumabtreated patients with multiple sclerosis. N Engl J Med 2013;368: 2240-2241.
33. Warnke C, Ramanujam R, Plavina T, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry 2013;84:1199-1205.
34. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68:295-303.
35. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in natalizumabtreated MS patients. Neurology 2013;81:1-7.
36. Munoz-Culla M, Irizar H, Castillo-Trivĩno T, et al.Blood miRNA expression pattern is a possible risk marker for natalizumabassociated progressive multifocal leukoencephalopathy in multiple sclerosis patients. Mult Scler 2014 May 22 [Epub ahead of print].